Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: Behavioral changes and pathology of the central nervous system

Brain Research

Volumn 1001, Issue 1-2, 2004, Pages 37-50

  Miklyaeva, Elena I ^a   Dong, Weijia ^a   Bureau, Alexandre ^b   Fattahie, Roya ^a   Xu, Yongqin ^a   Su, Meng ^c,e   Fick, Gordon H ^a   Huang, Jing Qi ^c,f   Igdoura, Suleiman ^c,g   Hanai, Nobuo ^d   Gravel, Roy A ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

^e UNIVERSITY OF COLORADO   (United States)

^f MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Behavioral phenotype of Tay Sachs mouse model; GM2 gangliosidosis; Hexa gene mutation; Lysosomal storage disease; Mouse model of Tay Sachs disease; Neuropathology of Tay Sachs mouse model

Indexed keywords

GANGLIOSIDE GM2;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR HYPOTHALAMUS; ARCUATE NUCLEUS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BEHAVIOR; BODY POSTURE; CATABOLISM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; GENE; HEXA GENE; HIPPOCAMPUS; HYDROLYSIS; HYPOTHALAMUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IMMUNODETECTION; LORDOSIS; MOUSE; MUSCLE WEAKNESS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYRIFORM CORTEX; SOMATOSENSORY CORTEX; SPASTICITY; SUBICULUM; TAY SACHS DISEASE; TREMOR; VISUAL IMPAIRMENT; WEIGHT REDUCTION; WILD TYPE;

EID: 10744226948     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.11.067     Document Type: Article

References (37)

1. Bertoni C., Li Y.T., Li S.C. Catabolism of asialo-GM2 in man and mouse. Specificity of human/mouse chimeric GM2 activator proteins. J. Biol. Chem. 274:1999;28612-28618.
2. Buxton D.F., Goodman D.C. Motor function and the corticospinal tracts in the dog and raccoon. J. Comp. Neurol. 129:1967;341-360.
3. Clarke K.A., Still J. Gait analysis in the mouse. Physiol. Behav. 66:1999;723-729.
4. Classen W. Behaviour, neurology and electrophysiology. Krinke G.J. The Laboratory Rat. 2000;419-436 Academic Press, New York.
5. Cohen-Tannoudji M., Marchand P., Akli S., Sheardown S.A., Puech J.P., Kress C., Gressens P., Nassogne M.C., Beccari T., Muggleton-Harris A.L. Disruption of murine hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm. Genome. 6:1995;844-849.
6. Crawley J. What's Wrong with my Mouse? 2000;Wiley, New York.
7. Deuschl G., Krack P. Tremors: differential diagnosis, neurophysiology, and pharmacology. Jankovic J., Tolosa E. Parkinson's Disease and Movement Disorders. 1998;419-452 Williams and Wilkins, Baltimore.
8. Efron B., Tibshirani R. An Introduction to the Bootstrap. 1993;Chapman & Hall, London.
9. Gravel R.A., Kaback M.M., Proia R.L., Sandhoff K., Suzuki K., Suzuki K. The GM2 gangliosidoses. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 2001;3827-3876 McGraw-Hill, New York.
10. Guidotti J.E., Mignon A., Haase G., Caillaud C., McDonell N., Kahn A., Poenaru L. Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase a-deficient knock-out mice. Hum. Mol. Genet. 8:1999;831-838.
11. Huang J.Q., Trasler J.M., Igdoura S., Michaud J., Hanal N., Gravel R.A. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 6:1997;1879-1885.
12. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (Berl.). 13:1966;222-257.
13. Jeyakumar M., Butters T.D., Cortina-Borja M., Hunnam V., Proia R.L., Perry V.H., Dwek R.A., Platt F.M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6388-6393.
14. Jeyakumar M., Norflus F., Tifft C.J., Cortina-Borja M., Butters T.D., Proia R.L., Perry V.H., Dwek R.A., Platt F.M. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 97:2001;327-329.
15. Jeyakumar M., Smith D., Eliott-Smith E., Cortina-Borja M., Reinkensmeier G., Butters T., Lemm T., Sandhoff K., Perry V., Dwek R., Platt F. An inducible mouse model of late onset Tay-Sachs disease. Neurobiol. Dis. 10:2002;201.
16. Jones B.J., Roberts D.J. The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J. Pharm. Pharmacol. 20:1968;302-304.
17. Lachmann R.H., Platt F.M. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Investig. Drugs. 10:2001;455-466.
18. Li S.C., Li Y.T., Moriya S., Miyagi T. Degradation of G(M1) and G(M2) by mammalian sialidases. Biochem. J. 360:2001;233-237.
19. Liu Y., Suzuki K., Reed J.D., Grinberg A., Westphal H., Hoffmann A., Doring T., Sandhoff K., Proia R.L. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2503-2508.
20. Liu Y., Wada R., Kawai H., Sango K., Deng C., Tai T., McDonald M.P., Araujo K., Crawley J.N., Bierfreund U., Sandhoff K., Suzuki K., Proia R.L. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 103:1999;497-505.
21. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
22. Mason C., Sotelo C. The cerebellum: a model for construction of a cortex. Perspect. Dev. Neurobiol. 5:1997;1-95.
23. McDaniel K.L., Moser V.C. Utility of a neurobehavioral screening battery for differentiating the effects of two pyrethroids, permethrin and cypermethrin. Neurotoxicol. Teratol. 15:1993;71-83.
24. Moser V.C., Cheek B.M., MacPhail R.C. A multidisciplinary approach to toxicological screening: III. Neurobehavioral toxicity. J. Toxicol. Environ. Health. 45:1995;173-210.
25. Nakamura K., Koike M., Shitara K., Kuwana Y., Kiuragi K., Igarashi S., Hasegawa M., Hanai N. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res. 54:1994;1511-1516.
26. Norflus F., Tifft C.J., McDonald M.P., Goldstein G., Crawley J.N., Hoffmann A., Sandhoff K., Suzuki K., Proia R.L. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101:1998;1881-1888.
27. Oya Y., Proia R.L., Norflus F., Tifft C.J., Langaman C., Suzuki K. Distribution of enzyme-bearing cells in GM2 gangliosidosis mice: regionally specific pattern of cellular infiltration following bone marrow transplantation. Acta Neuropathol. (Berl). 99:2000;161-168.
28. Phaneuf D., Wakamatsu N., Huang J.Q., Borowski A., Peterson A.C., Fortunato S.R., Ritter G., Igdoura S.A., Morales C.R., Benoit G., Akerman B.R., Leclerc D., Hanai N., Marth J.D., Trasler J.M., Gravel R.A. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 5:1996;1-14.
29. Platt F.M., Neises G.R., Reinkensmeier G., Townsend M.J., Perry V.H., Proia R.L., Winchester B., Dwek R.A., Butters T.D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276:1997;428-431.
30. Ross J.F., Handley D.E., Fix A.S., Lawhorn G.T., Carr G.J. Quantification of the hindlimb extensor thrust response in rats. Neurotoxicol. Teratol. 19:1997;405-411.
31. Sandhoff K., Conzelmann E., Nehrkorn H. Specificity of human liver hexosaminidases A and B against glycosphingolipids GM2 and GA2. Purification of the enzymes by affinity chromatography employing specific elution, Hoppe Seylers. Z. Physiol. Chem. 358:1977;779-787.
32. Sango K., Yamanaka S., Hoffmann A., Okuda Y., Grinberg A., Westphal H., McDonald M.P., Crawley J.N., Sandhoff K., Suzuki K. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11:1995;170-176.
33. Taniike M., Yamanaka S., Proia R.L., Langaman C., Bone-Turrentine T., Suzuki K. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol. (Berl). 89:1995;296-304.
34. Thompson R. A Behavioral Atlas of the Rat Brain. 1978;Oxford Univ. Press, NY.
35. Wenger D.A., Okada S., O'Brien J.S. Studies on the substrate specificity of hexosaminidase A and B from liver. Arch. Biochem. Biophys. 153:1972;116-129.
36. Yamanaka S., Johnson M.D., Grinberg A., Westphal H., Crawley J.N., Taniike M., Suzuki K., Proia R.L. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9975-9979.
37. Yuziuk J.A., Bertoni C., Beccari T., Orlacchio A., Wu Y.Y., Li S.C., Li Y.T. Specificity of mouse GM2 activator protein and beta-N- acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2. J. Biol. Chem. 273:1998;66-72.